Limits...
A review of time courses and predictors of lipid changes with fenofibric acid-statin combination.

Filippatos TD - Cardiovasc Drugs Ther (2012)

Bottom Line: Fibrates activate peroxisome proliferator activated receptor α and exert beneficial effects on triglycerides, high-density lipoprotein cholesterol, and low density lipoprotein subspecies.The combination of FA with simvastatin, atorvastatin and rosuvastatin resulted in greater improvement of the overall lipid profile compared with the corresponding statin dose.The long-term efficacy of FA combined with low- or moderate- dose statin has been demonstrated in a wide range of patients, including patients with type 2 diabetes mellitus, metabolic syndrome, or elderly subjects.

View Article: PubMed Central - PubMed

Affiliation: Department of Internal Medicine, School of Medicine, University of Ioannina, 45110 Ioannina, Greece. filtheo@gmail.com

ABSTRACT
Fibrates activate peroxisome proliferator activated receptor α and exert beneficial effects on triglycerides, high-density lipoprotein cholesterol, and low density lipoprotein subspecies. Fenofibric acid (FA) has been studied in a large number of patients with mixed dyslipidemia, combined with a low- or moderate-dose statin. The combination of FA with simvastatin, atorvastatin and rosuvastatin resulted in greater improvement of the overall lipid profile compared with the corresponding statin dose. The long-term efficacy of FA combined with low- or moderate- dose statin has been demonstrated in a wide range of patients, including patients with type 2 diabetes mellitus, metabolic syndrome, or elderly subjects. The FA and statin combination seems to be a reasonable option to further reduce cardiovascular risk in high-risk populations, although trials examining cardiovascular disease events are missing.

Show MeSH

Related in: MedlinePlus

Lipid alterations (%) with the combination of fenofibric acid (FA) 135 mg/day with rosuvastatin compared with rosuvastatin alone [24]. *p < 0.05 vs. corresponding statin dose. &p < 0.05 vs. FA monotherapy. Bars represent mean ± SEM. The numbers with white color represent the baseline values, whereas the numbers with black color represent the percent changes. HDL-C = high-density lipoprotein cholesterol, TG = triglycerides, LDL-C = low-density lipoprotein cholesterol
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3368211&req=5

Fig4: Lipid alterations (%) with the combination of fenofibric acid (FA) 135 mg/day with rosuvastatin compared with rosuvastatin alone [24]. *p < 0.05 vs. corresponding statin dose. &p < 0.05 vs. FA monotherapy. Bars represent mean ± SEM. The numbers with white color represent the baseline values, whereas the numbers with black color represent the percent changes. HDL-C = high-density lipoprotein cholesterol, TG = triglycerides, LDL-C = low-density lipoprotein cholesterol

Mentions: The FA/rosuvastatin study randomized 1,455 patients of whom 1,377 were available for analysis [24]. FA + rosuvastatin 20 mg/day resulted in a significantly greater increase in HDL-C (19.0 % vs. 10.3 %, p < 0.001) and a significantly greater decrease in TG (−42.9 % vs. −25.6 %, p < 0.001) and VLDL-C (−50.6 % vs. −42.1 %, p = 0.038) levels compared with rosuvastatin 20 mg/day monotherapy (Fig. 4). Furthermore, FA + rosuvastatin 20 mg/day produced a significantly greater LDL-C reduction (−38.8 % vs. −6.5 %, p < 0.001) compared with FA monotherapy. Similar results were observed when FA + rosuvastatin 10 mg/day was compared with rosuvastatin 10 mg/day or with FA monotherapy (Fig. 4). FA + rosuvastatin 10 mg/day resulted in significantly greater improvements in non-HDL-C compared with FA (p < 0.001) and rosuvastatin 10 mg/day monotherapy (p < 0.001), as well as in hsCRP (p = 0.013) and VLDL-C (p < 0.001) compared with rosuvastatin 10 mg/day monotherapy. FA + rosuvastatin 20 mg/day resulted in a greater improvement in hsCRP levels compared with rosuvastatin 20 mg/day monotherapy (p = 0.01) [24].Fig. 4


A review of time courses and predictors of lipid changes with fenofibric acid-statin combination.

Filippatos TD - Cardiovasc Drugs Ther (2012)

Lipid alterations (%) with the combination of fenofibric acid (FA) 135 mg/day with rosuvastatin compared with rosuvastatin alone [24]. *p < 0.05 vs. corresponding statin dose. &p < 0.05 vs. FA monotherapy. Bars represent mean ± SEM. The numbers with white color represent the baseline values, whereas the numbers with black color represent the percent changes. HDL-C = high-density lipoprotein cholesterol, TG = triglycerides, LDL-C = low-density lipoprotein cholesterol
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3368211&req=5

Fig4: Lipid alterations (%) with the combination of fenofibric acid (FA) 135 mg/day with rosuvastatin compared with rosuvastatin alone [24]. *p < 0.05 vs. corresponding statin dose. &p < 0.05 vs. FA monotherapy. Bars represent mean ± SEM. The numbers with white color represent the baseline values, whereas the numbers with black color represent the percent changes. HDL-C = high-density lipoprotein cholesterol, TG = triglycerides, LDL-C = low-density lipoprotein cholesterol
Mentions: The FA/rosuvastatin study randomized 1,455 patients of whom 1,377 were available for analysis [24]. FA + rosuvastatin 20 mg/day resulted in a significantly greater increase in HDL-C (19.0 % vs. 10.3 %, p < 0.001) and a significantly greater decrease in TG (−42.9 % vs. −25.6 %, p < 0.001) and VLDL-C (−50.6 % vs. −42.1 %, p = 0.038) levels compared with rosuvastatin 20 mg/day monotherapy (Fig. 4). Furthermore, FA + rosuvastatin 20 mg/day produced a significantly greater LDL-C reduction (−38.8 % vs. −6.5 %, p < 0.001) compared with FA monotherapy. Similar results were observed when FA + rosuvastatin 10 mg/day was compared with rosuvastatin 10 mg/day or with FA monotherapy (Fig. 4). FA + rosuvastatin 10 mg/day resulted in significantly greater improvements in non-HDL-C compared with FA (p < 0.001) and rosuvastatin 10 mg/day monotherapy (p < 0.001), as well as in hsCRP (p = 0.013) and VLDL-C (p < 0.001) compared with rosuvastatin 10 mg/day monotherapy. FA + rosuvastatin 20 mg/day resulted in a greater improvement in hsCRP levels compared with rosuvastatin 20 mg/day monotherapy (p = 0.01) [24].Fig. 4

Bottom Line: Fibrates activate peroxisome proliferator activated receptor α and exert beneficial effects on triglycerides, high-density lipoprotein cholesterol, and low density lipoprotein subspecies.The combination of FA with simvastatin, atorvastatin and rosuvastatin resulted in greater improvement of the overall lipid profile compared with the corresponding statin dose.The long-term efficacy of FA combined with low- or moderate- dose statin has been demonstrated in a wide range of patients, including patients with type 2 diabetes mellitus, metabolic syndrome, or elderly subjects.

View Article: PubMed Central - PubMed

Affiliation: Department of Internal Medicine, School of Medicine, University of Ioannina, 45110 Ioannina, Greece. filtheo@gmail.com

ABSTRACT
Fibrates activate peroxisome proliferator activated receptor α and exert beneficial effects on triglycerides, high-density lipoprotein cholesterol, and low density lipoprotein subspecies. Fenofibric acid (FA) has been studied in a large number of patients with mixed dyslipidemia, combined with a low- or moderate-dose statin. The combination of FA with simvastatin, atorvastatin and rosuvastatin resulted in greater improvement of the overall lipid profile compared with the corresponding statin dose. The long-term efficacy of FA combined with low- or moderate- dose statin has been demonstrated in a wide range of patients, including patients with type 2 diabetes mellitus, metabolic syndrome, or elderly subjects. The FA and statin combination seems to be a reasonable option to further reduce cardiovascular risk in high-risk populations, although trials examining cardiovascular disease events are missing.

Show MeSH
Related in: MedlinePlus